Login to Your Account

Celldex Flying Solo as Pfizer Bails on CDX-110 Partnership

By Jennifer Boggs

Tuesday, September 7, 2010
Though shares of Celldex Therapeutics Inc. plunged 26.2 percent on the news, President and CEO Anthony Marucci sees Pfizer Inc.'s decision to return rights to brain cancer vaccine CDX-110 (rindopepimut) as a positive event for his company. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription